Author(s):
Gitesh Chandra, Harshit Narang, Anish Chandy
Email(s):
anishc@cecbilaspur.ac.in
DOI:
10.52711/0975-4377.2026.00029 
Address:
Gitesh Chandra1, Harshit Narang1, Anish Chandy2*
1Students, Chouksey School of Pharmacy, CEC, Bilaspur, Chhattisgarh, India.
2Associate Professor, Chouksey School of Pharmacy, CEC, Bilaspur, Chhattisgarh, India.
*Corresponding Author
Published In:
Volume - 18,
Issue - 3,
Year - 2026
ABSTRACT:
Background: Type 2 diabetes mellitus (T2DM) affects approximately 90% of diabetic patients globally, requiring effective pharmacological interventions for optimal glycemic control. Metformin hydrochloride, a first-line antidiabetic agent, belongs to Biopharmaceutics Classification System (BCS) Class III with high solubility but poor membrane permeability, resulting in limited oral bioavailability of 50-60%. Solid lipid nanoparticles (SLNs) offer a promising strategy to overcome these biopharmaceutical limitations. Objective: This study aimed to formulate and characterize metformin-loaded solid lipid nanoparticles (MTF-SLNs) using hot melt homogenization-ultrasonication technique to enhance drug permeability, bioavailability, and therapeutic efficacy in T2DM management. Methods: MTF-SLNs were prepared using hot homogenization followed by ultrasonication method employing stearic acid as the solid lipid, polysorbate 80 as surfactant, and sorbitol as cryoprotectant. The formulations were systematically optimized and characterized for particle size, polydispersity index (PDI), zeta potential, entrapment efficiency, surface morphology, drug-excipient compatibility, crystallinity, and in vitro drug release profile. Stability studies and comparative dissolution studies were performed to assess formulation performance. Results: The optimized MTF-SLN formulation exhibited excellent physicochemical characteristics with mean particle size of 262.1 nm, PDI of 0.352, zeta potential of -42.5 mV, and high entrapment efficiency of 95.8%. Transmission electron microscopy confirmed spherical morphology with smooth surface. Differential scanning calorimetry revealed amorphous state of metformin within the lipid matrix. The formulation demonstrated sustained drug release pattern with 78.3% release over 12 hours following Higuchi kinetics. Permeability studies showed 5-fold enhancement compared to pure metformin. Conclusion: Metformin-loaded solid lipid nanoparticles represent a viable and effective nanocarrier system for enhanced oral delivery of metformin in T2DM management. The formulation demonstrated improved permeability, sustained release characteristics, and enhanced stability, offering potential for reduced dosing frequency and improved patient compliance.
Cite this article:
Gitesh Chandra, Harshit Narang, Anish Chandy. Formulation and Characterization of Metformin Loaded Solid Lipid Nanoparticles for Management of Type 2 Diabetes Mellitus. Research Journal of Pharmaceutical Dosage Forms and Technology.2026; 18(3):193-2. doi: 10.52711/0975-4377.2026.00029
Cite(Electronic):
Gitesh Chandra, Harshit Narang, Anish Chandy. Formulation and Characterization of Metformin Loaded Solid Lipid Nanoparticles for Management of Type 2 Diabetes Mellitus. Research Journal of Pharmaceutical Dosage Forms and Technology.2026; 18(3):193-2. doi: 10.52711/0975-4377.2026.00029 Available on: https://rjpdft.com/AbstractView.aspx?PID=2026-18-3-4
6. REFERENCES:
1. American Diabetes Association. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes. Diabetes Care. 2024; 47(Supplement 1): S20-S42. https://doi.org/10.2337/dc24-S002
2. Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., Stein, C., Basit, A., Chan, J. C., Mbanya, J. C., Pavkov, M. E., Ramachandaran, A., Wild, S. H., James, S., Herman, W. H., Zhang, P., Bommer, C., Kuo, S., Boyko, E. J., and Magliano, D. J. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Research and Clinical Practice. 2022; 183: 109119. https://doi.org/10.1016/j.diabres.2021.109119
3. International Diabetes Federation. (2021). IDF Diabetes Atlas (10th ed.). https://diabetesatlas.org/
4. DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., Simonson, D. C., Testa, M. A., and Weiss, R. Type 2 diabetes mellitus. Nature Reviews Disease Primers. 2015; 1: 15019. https://doi.org/10.1038/nrdp.2015.19
5. Forbes, J. M., and Cooper, M. E. Mechanisms of diabetic complications. Physiological Reviews. 2013; 93(1): 137-188. https://doi.org/10.1152/physrev.00045.2011
6. Mohamed, H. A., El-Sayed, N. M., Ismail, M. M., Osman, D. A., and Fahmy, R. H. Metformin-loaded nanoparticles reduce hyperglycemia-induced oxidative stress and vascular dysfunction. Scientific Reports. 2024; 14: 30682. https://doi.org/10.1038/s41598-024-81427-6
7. Chatterjee, S., Khunti, K., and Davies, M. J. Type 2 diabetes. The Lancet. 2017; 389(10085): 2239-2251. https://doi.org/10.1016/S0140-6736(17)30058-2
8. Kalra, S., Bahendeka, S., Sahay, R., Ghosh, S., Kilov, G., Bavuma, C. M., Jawad, F., Azad Khan, A. K., Katulanda, P., Simons, M., Mgunda, F., and Viswanathan, V. Consensus on medical nutrition therapy for diabesity (obesity and type 2 diabetes mellitus) in the continuum of care. Diabetes and Metabolic Syndrome: Clinical Research and Reviews. 2019; 13(1): 582-590. https://doi.org/10.1016/j.dsx.2018.11.036
9. American Diabetes Association. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2024. Diabetes Care. 2024; 47(Supplement 1): S158-S178. https://doi.org/10.2337/dc24-S009
10. Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., Rossing, P., Tankova, T., Tsapas, A., and Buse, J. B. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022; 45(11): 2753-2786. https://doi.org/10.2337/dci22-0034
11. Rena, G., Hardie, D. G., and Pearson, E. R. The mechanisms of action of metformin. Diabetologia. 2017; 60(9): 1577-1585. https://doi.org/10.1007/s00125-017-4342-z
12. Foretz, M., Guigas, B., and Viollet, B. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Nature Reviews Endocrinology. 2023; 19(11): 633-652. https://doi.org/10.1038/s41574-023-00833-4
13. Metry, M., Abdelbary, G., Ahmed, H., Kets, E., and Annaert, P. Biowaiver monographs for immediate release solid oral dosage forms: Metformin hydrochloride. Journal of Pharmaceutical Sciences. 2021; 110(4): 1513-1526. https://doi.org/10.1016/j.xphs.2021.01.011
14. Hou, Z., Li, Y., Huang, Y., Zhou, C., Lin, J., Wang, Y., Cui, F., Zhou, S., Jia, M., Ye, S., and Zhang, Q. Biowaiver extension potential to BCS Class III high solubility-low permeability drugs: bridging evidence for metformin immediate-release tablet. European Journal of Pharmaceutical Sciences. 2004; 22(4): 297-304. https://doi.org/10.1016/j.ejps.2004.03.016
15. Chou, F. C., Huang, P. W., and Huang, T. W. (). Determination of the partition coefficient and acid dissociation constant of metformin by capillary electrophoresis. Journal of Food and Drug Analysis. 2002; 10(2): 75-79.
16. Graham, G. G., Punt, J., Arora, M., Day, R. O., Doogue, M. P., Duong, J. K., Furlong, T. J., Greenfield, J. R., Greenup, L. C., Kirkpatrick, C. M., Ray, J. E., Timmins, P., and Williams, K. M. Clinical pharmacokinetics of metformin. Clinical Pharmacokinetics. 2011; 50(2): 81-98. https://doi.org/10.2165/11534750-000000000-00000
17. Marathe, P. H., Gao, H. X., and Close, K. L. American Diabetes Association Standards of Medical Care in Diabetes 2017. Journal of Diabetes. 2000; 9(4): 320-324. https://doi.org/10.1111/1753-0407.12524
18. Gong, L., Goswami, S., Giacomini, K. M., Altman, R. B., and Klein, T. E. Metformin pathways: pharmacokinetics and pharmacodynamics. Pharmacogenetics and Genomics. 2012; 22(11): 820-827. https://doi.org/10.1097/FPC.0b013e3283559b22
19. Zhou, K., Donnelly, L. A., Kimber, C. H., Donnan, P. T., Doney, A. S., Leese, G., Hattersley, A. T., McCarthy, M. I., Morris, A. D., Palmer, C. N., and Pearson, E. R. Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study. Diabetes. 2009; 58(6): 1434-1439. https://doi.org/10.2337/db08-0896
20. Patra, J. K., Das, G., Fraceto, L. F., Campos, E. V. R., Rodriguez-Torres, M. D. P., Acosta-Torres, L. S., Diaz-Torres, L. A., Grillo, R., Swamy, M. K., Sharma, S., Habtemariam, S., and Shin, H. S. Nano based drug delivery systems: Recent developments and future prospects. Journal of Nanobiotechnology. 2018; 16(1): 71. https://doi.org/10.1186/s12951-018-0392-8
21. Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., and Langer, R. Engineering precision nanoparticles for drug delivery. Nature Reviews Drug Discovery. 2021; 20(2): 101-124. https://doi.org/10.1038/s41573-020-0090-8
22. Shi, J., Kantoff, P. W., Wooster, R., and Farokhzad, O. C. Cancer nanomedicine: progress, challenges and opportunities. Nature Reviews Cancer. 2017; 17(1): 20-37. https://doi.org/10.1038/nrc.2016.108
23. Müller, R. H., Mäder, K., and Gohla, S. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. European Journal of Pharmaceutics and Biopharmaceutics. 2000; 50(1): 161-177. https://doi.org/10.1016/S0939-6411(00)00087-4
24. Mehnert, W., and Mäder, K. Solid lipid nanoparticles: Production, characterization and applications. Advanced Drug Delivery Reviews. 2012; 64: 83-101. https://doi.org/10.1016/j.addr.2012.09.021
25. Müller, R. H., Radtke, M., and Wissing, S. A. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Advanced Drug Delivery Reviews. 2002; 54(Supplement 1): S131-S155. https://doi.org/10.1016/S0169-409X(02)00118-7
26. Gasco, M. R. Method for producing solid lipid microspheres having a narrow size distribution. U.S. Patent No. 1993; 5: 250,236.
27. Khosa, A., Reddi, S., and Saha, R. N. Nanostructured lipid carriers for site-specific drug delivery. Biomedical Pharmacotherapy. 2018; 103: 598-613. https://doi.org/10.1016/j.biopha.2018.04.055
28. Das, S., and Chaudhury, A. Preparation of solid lipid nanoparticles and nanostructured lipid carriers using hot melt extrusion technology. Pharmaceutical Development and Technology. 2020; 25(10): 1158-1170. https://doi.org/10.1080/10837450.2020.1809000
29. Qushawy, M., Nasr, A., Abd-Alhaseeb, M., and Swidan, S. Optimized nanostructured lipid carriers for metformin: Enhanced anti-inflammatory activity and protection against type 2 diabetes-induced organ damage. International Journal of Nanomedicine. 2025; 20: 2345-2365. https://doi.org/10.2147/IJN.S445328
30. Cassayre, M., Provost, C., Boudier, A., Clarot, I., and Maincent, P. Optimization of solid lipid nanoparticle formulation using design of experiments and artificial intelligence approaches. Pharmaceutics. 2025; 17(7): 892. https://doi.org/10.3390/pharmaceutics17070892
31. Danaei, M., Dehghankhold, M., Ataei, S., Hasanzadeh Davarani, F., Javanmard, R., Dokhani, A., Khorasani, S., and Mozafari, M. R. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics. 2018; 10(2): 57. https://doi.org/10.3390/pharmaceutics10020057
32. Honary, S., and Zahir, F. Effect of zeta potential on the properties of nano-drug delivery systems - A review (Part 2). Tropical Journal of Pharmaceutical Research. 2013; 12(2): 265-273. https://doi.org/10.4314/tjpr.v12i2.20
33. zur Mühlen, A., Schwarz, C., and Mehnert, W. Solid lipid nanoparticles (SLN) for controlled drug delivery – Drug release and release mechanism. European Journal of Pharmaceutics and Biopharmaceutics. 1998; 45(2): 149-155. https://doi.org/10.1016/S0939-6411(97)00150-1
34. Freitas, C., and Müller, R. H. Correlation between long-term stability of solid lipid nanoparticles (SLN™) and crystallinity of the lipid phase. European Journal of Pharmaceutics and Biopharmaceutics. 1999; 47(2): 125-132. https://doi.org/10.1016/S0939-6411(98)00074-5
35. Thakur, N., Garg, G., and Sharma, P. K. Permeability enhancement of a BCS Class III drug: Metformin using lipid-based nanoparticles. International Journal of Applied Pharmaceutics, 2025; 17(3): 45-53. https://doi.org/10.22159/ijap.2025v17i3.53483